Faecal incontinence Digestive System Faecal incontinence
Conditions
Interventions
All patients received loperamide. Most patients were advised to start by taking one tablet (2 mg) twice a day. Patients with a tendency to constipation were advised to start on one tablet daily. All p
Sponsors
University of Otago (New Zealand)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Over eighteen years of age 2. Referred to an outpatient colorectal service with the primary presenting problem of chronic incontinence to mucus, liquid and/or solid stool 3. Living independently 4. Able to read and complete the study information and questionnaires
Exclusion criteria
Exclusion criteria: 1. Full thickness rectal prolapse 2. Inflammatory bowel disease 3. Other pathologies requiring surgery 4. Diabetes (chosen supplement contraindicated) 5. Previous treatment for faecal incontinence
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Faecal Incontinence Severity Index (FISI) patient-weighted score, measured at baseline, 6 weeks at cross over and at 12 weeks at conclusion of the second treatment period. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. 36-item Short Form health survey (SF-36) 2. Faecal Incontinence Quality of Life scale (FIQL) All questionnaires were performed at baseline, 6 weeks at cross over and at 12 weeks at conclusion of the second treatment period. | — |
Countries
New Zealand
Outcome results
None listed